论文部分内容阅读
目的:评价单用坦索罗辛(商品名:哈乐)治疗BPH的临床疗效。方法:将200例BPH患者随机分为坦索罗辛组、坦索罗辛+翁沥通组及坦索罗辛+保列治组,比较治疗后患者前列腺体积、IPSS症状评分、剩余尿量、最大尿流率变化以及药物费用。结果:三组在降低IPSS症状评分、增大最大尿流率、减少膀胱剩余尿和缩小前列腺体积上的差异无统计学意义(P>0.05),但单用坦索罗辛组药物费用最低。结论:单用坦索罗辛即可很好地控制BPH。
PURPOSE: To evaluate the clinical efficacy of tamsulosin alone (trade name: Harmony) in the treatment of BPH. Methods: 200 patients with BPH were randomly divided into tamsulosin group, tamsulosin + Wenglton group and tamsulosin + Proliferation group. Prostate volume, IPSS symptom score, residual urine volume , Changes in maximum flow rate, and drug costs. Results: There was no significant difference among the three groups in reducing IPSS symptom score, increasing maximal uroflow rate, reducing bladder residual urine and reducing prostate volume (P> 0.05). However, the tamsulosin group had the lowest drug cost. Conclusion: Tamsulosin alone can control BPH well.